Avantor, Inc. Q3 FY2024 earnings call

Delivered a solid quarter with reported revenue of $1.71 billion, while organic revenue declined 0.7% year-over-year. Adjusted EBITDA margin was 17.6%, and adjusted EPS increased to $0.26. Cost transformation is ahead of plan, and free cash flow guidance has been raised. The divestiture of clinical services assets was successfully closed, providing $500 million in after-tax proceeds. Made progress in long-term growth strategy, including launching new products in bioprocessing and lab segments, opening a new innovation center, and receiving an award for the new cell business. Improved supply chain operations and advanced sustainability efforts.

Laboratory Solutions: Revenue was $1.17 billion for the quarter, growing 0.6% organically year-over-year. Consumables and services performed well, with equipment and instrumentation demand improving modestly. Adjusted operating income was $152 million with a 12.9% margin. Bioscience Production: Revenue was $543 million, an organic decline of approximately 3.5% versus prior year. Bioprocessing, making up about two thirds of the segment, outperformed expectations and was roughly flat year-over-year. Biomaterials performed in line, while advanced technologies were somewhat below expectations. Adjusted operating income was $138 million, representing a 25.4% margin.

Reiterated full year P&L guidance, adjusting for the clinical services divestiture. Raised free cash flow guidance from $600 million to $650 million to more than $750 million. Expected adjusted EBITDA margin of 17.3% to 17.8% and adjusted EPS of $0.95 to $1.03 for the full year. Laboratory Solutions is expected to have organic growth flat to modestly up in Q4, with full year flat to low single-digit declines. Bioscience Production is expected to have organic growth low to mid-single digits in Q4, with full year low single-digit declines.

Uncertainties in end market conditions, including potential impacts from cautious spending in biopharma and headwinds in the semiconductor sector. Macroeconomic factors could also affect revenue and margin performance.

Q: Dan Brennan asked about the implied fourth quarter guide and Bioscience Production guidance.

A: Brent Jones discussed segment outlooks, noting return to growth in Laboratory Solutions and mid- to high growth in bioprocessing in Q4.

Q: Doug Schenkel inquired about BPS segment performance and margin.

A: Michael Stubblefield and Brent Jones talked about BPS segments, with bioprocessing outperforming and margin impacts from mix and freight expense.

Q: Tycho Peterson asked about semi sector pressure and new cell business.

A: Michael Stubblefield and Brent Jones discussed semi sector headwinds and positive trends in the new cell business.

Q: Michael Ryskin asked about clinical services divestiture impact on 2025 and cost savings.

A: Michael Stubblefield and Brent Jones explained the divestiture's impact and ahead-of-plan cost savings.

Q: Vijay Kumar asked about semi sector outlook and bioprocessing order trends.

A: Michael Stubblefield discussed semi sector headwinds and positive order trends in bioprocessing.

Q: Dan Leonard asked about 2025 EBITDA margin target and Lab Solutions market share.

A: Michael Stubblefield and Brent Jones talked about margin targets and Lab Solutions' market share growth.

Q: Conor McNamara asked about Q4 guidance and M&A potential.

A: Brent Jones and Michael Stubblefield discussed Q4 guidance and future M&A plans.

Q: Daniel Arias asked about Lab Solutions growth and consumables.

A: Michael Stubblefield discussed Lab Solutions growth, pricing, and consumables trends.

Q: Rachel Vatnsdal asked about Lab Solutions pricing and Bioscience Production segments.

A: Michael Stubblefield and Michael Stubblefield talked about Lab Solutions pricing and Bioscience Production segment exposures.

Q: Luke Sergott asked about Bioscience Production margins and equipment drag.

A: Michael Stubblefield discussed Bioscience Production margins and equipment trends.

Q: Tejas Savant asked about biotech pharma and Europe.

A: Michael Stubblefield talked about biotech pharma dynamics and positive trends in Europe.

Q: Patrick Donnelly asked about biotech pharma spend and gross margins.

A: Michael Stubblefield and Brent Jones discussed biotech pharma spend and future margin considerations.